had Hb Hoshida (β43Glu→Gln). All 4 patients with abnormal peaks at the S window on HPLC (mean retention time, 0.91 min) had Hb Queens (α1 34Leu→Arg). All 10 patients with variant peaks were heterozygous, and they had abnormal bands within the Hb S/Hb G/Hb D area on cellulose acetate Hb electrophoresis.

Hb G Coushatta has been found in Koreans, Chinese, and in some Japanese families (6). This variant usually leads to underestimation of Hb A1c as we noted in our patients. The abnormal peak between Hb A1c and Hb A2 seemed to be that of glycated Hb G Coushatta, as Ogawa et al. (7) have indicated, and Hb G Coushatta is thought to coelute with the normal Hb A1c peak. Hb Hoshida has been reported in a few Japanese families and in 1 Yugoslavian family, and Hb Queens has been found in Koreans, Chinese, Japanese, and Vietnamese (6).

We found increased Hb F concentrations in 15 patients. Gene dosage analysis revealed that the ratios of the β-globin gene to the albumin gene were ~0.5 in 2 patients, which suggested heterozygous deletion of the β-globin gene. One of the 2 patients had no phenotypic abnormality other than the increased Hb F (19.5%), suggesting deleterional hereditary persistence of fetal Hb. The other patient had a history of chronic microcytic hypochromic anemia. The increased Hb A2 concentration, the decreased osmolality fragility, and the typical findings on the peripheral blood smear suggested deleterional β-thalassemia minor. The remaining 13 patients showed negative results for all molecular analyses on the β- and γ-globin genes. Only the XmnI site sequence variation (c.−158C→T) on the promoter of the Gγ-globin gene was noted in 10 patients, including 1 homozygote. This sequence variation has been shown to influence the Hb F concentrations in apparently healthy individuals (8). Hereditary persistence of fetal Hb was suspected because no phenotypic or laboratory abnormalities other than the increased Hb F concentrations were seen.

In conclusion, the incidences of Hb var and high Hb F concentrations were estimated to be 1 in 2700 and 1 in 1800, respectively. The most common Hb var in Koreans were Hb G Coushatta and Hb Queens, which could be presumed from their characteristic HPLC patterns. The known sequence variations in the β-, Gγ-, or Aγ-globin genes that cause high Hb F are rare in Koreans. Considering that Hb var and high Hb F concentrations are not uncommon, more effort should be made to estimate the correct Hb A1c value in Korean patients with diabetes.

References
1. Goldstein DE, Little RR, Lorenz RA, Malone JL, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761–73.
2. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47:153–63.
3. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann NY Acad Sci 1998;850:38–44.
4. Harteveld KL, Heister AJ, Giordano PC, Losekoot M, Bernini LF. Rapid detection of point mutations and polymorphisms of the γ-globin genes by DGGE and SSCE. Hum Mutat 1996;7:114–22.
5. Efremov DG, Dimovski AJ, Huisman TH. The −158 (C→T) promoter mutation is responsible for the increased transcription of the 3′ gamma gene in the Atlanta type of hereditary persistence of fetal hemoglobin. Blood 1994;83: 3350–5.
6. Hardison RC, Chui DH, Giardine B, Riemer C, Patrinos GP, Anagnostou N, et al. HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat 2002;19:225–33.
7. Ogawa K, Bando T, Ogawa M, Miyazaki A, Nakamishi T, Shimizu A. Hemoglobin variant HbG-Coushatta (β22 Glu→Ala) found by dissociation of blood glucose from values of HbA1C measured by HPLC. Intern Med 2003;42:781–7.
8. Sampietro M, Thein SL, Contreras M, Pazmany L. Variation of HbF and Fcell number with the Gγ XmnI (C-T) polymorphism in normal individuals. Blood 1992;79:832–3.

Seung-Tae Lee
Myong Soo Kim
Dae Yong Choi
Sun Kyung Kim
Chang-Seok Ki
Department of Laboratory Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, Korea

Preparation of a Chimeric Armored RNA as a Versatile Calibrator for Multiple Virus Assays

To the Editor:

As with all diagnostic techniques, molecular testing requires careful quality control (1–5). In detection of RNA viruses, which are often present at low concentrations and are prone to degradation, stringent monitoring is needed for all aspects of assay performance, including virus lysis, RNA isolation, reverse transcription, amplification, and detection steps. Among many proposed RNA control preparations (4, 5), armored RNA is currently the most suitable for clinical applications as it carries the viral RNA target of interest in a form that is ribonuclease-resistant, noninfectious, and stable after prolonged incubation in clinical matrices, and the preparations are substantially less expensive to manufacture than virus-infected plasma (6–8). Thus, armored RNA has been applied as a positive control for a variety of RNA viruses (9).

Because most commercial armored RNA preparations contain exogenous sequences of <500 nucleotides (9), separate armored RNA species are often prepared for calibration of each target in multiple virus assays. To reduce costs and simplify multi-virus detection, we are seeking to produce a single chimeric armored RNA species that might be used as a positive control for multiple viral targets. We consider this task to be feasible because the inventors of armored RNA predicted that, theoretically, at least 2 kb of nonbacteriophage RNA sequence might be encapsulated (8). As proof of this

* Address correspondence to this author at: Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-Dong, Gangnam-Gu, Seoul 135-710, Korea. Fax 82-2-3410-2719; e-mail changski@skku.edu.

DOI: 10.1373/clinchem.2006.069617
principle, we tried to directly package a 1200-nucleotide-long foreign RNA sequence containing gene fragments of hepatitis C virus (HCV), HIV-1, severe acute respiratory syndrome coronavirus 1 (SARS-CoV1), and SARS-CoV2 into the original armored RNA production vector pAR-1 (8).

We spliced the 4 target cDNA sequences by overlapping extension (10). After cloning the 4-target chimeric sequence (see the Data Supplement that accompanies the online version of this letter at http://www.clinchem.org/content/vol52/issue7/) for the sequence information of the 4 fragments as well as the primers and probes used) into pAR-1, we used a simple but straightforward procedure to confirm the production of armored RNA and to purify it. Briefly, after induction of armored RNA production, we treated the supernatant of Escherichia coli cell lysate with RNase A and DNase I. On testing with agarose gel electrophoresis, if armored RNA was produced, a single DNA band of ~1.5 kb might be visible. We then cut the band from the gel and put in a dialysis bag for electroelution. Using this method, we successfully expressed and purified the chimeric armored RNA. We used a pure RNA transcript fragment of SARS-CoV2 (BNI) to calibrate the chimeric armored RNA, then used the chimeric armored RNA to prepare calibrators of the 4 real-time reverse transcription-PCR (RT-PCR) assays (Fig. 1; also see Fig. 1 in the online Data Supplement) based on displacing probes (11). The linear range for each assay did not change when the calibrators were stored at 37 °C for 2 weeks, at 4 °C for 6 months, or at −20 °C for 1 year.

Our work indicates that multiple target sequences can be encapsulated into a single armored RNA species to serve as a common calibrator for detection of different RNA viruses. Chimeric armored RNA of even larger size may be prepared similarly, as indicated by our finding that by deleting some disposable sequences between the multiple cloning site and the transcription terminator, we were able to increase packaging capacity of the pAR-1 vector without affecting packaging efficiency (data not shown). Thus, the chimeric, multitarget approach for armored RNA preparation is practical and could reduce the labor and cost for quality control of multiplex RNA virus assays.

We thank Xilin Zhao and Karl Drlica for critical comments on the manuscript. This work was partially supported by the Natural Science Foundation of Fujian Government (2003Y004), by the Xiamen Municipal Commission of Science and Technology Key Program, and by the Xiamen University Action Project.

References

1. Hoorfar J, Malorny B, Abdulmawjood A, Cook N, Wagner M, Fach P. Practical considerations in design of internal amplification controls for diagnostic PCR assays. J Clin Microbiol 2004;42:1863–8.

2. Nolle FS. Novel internal controls for real-time PCR assays. Clin Chem 2004;50:801–2.

3. Walkerpeach CR, Pasloske BL. DNA bacteriophage as controls for clinical viral testing. Clin Chem 2004;50:1970–1.

4. Burggraf S, Olgemoller S. Straightforward procedure for internal control of real-time reverse transcription amplification assays. Clin Chem 2005;51:1508–10.

5. Dingle KE, Crook D, Jeffery K. Stable and noncompetitive RNA internal control for routine clinical diagnostic reverse transcription-PCR. J Clin Microbiol 2004;42:1003–11.

6. Pasloske BL, Walkerpeach CR, Obermoeller RD, Winkler M, Dubois DB. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J Clin Microbiol 1998;36:3590–4.

7. WalkerPeach CR, Winkler M, Dubois DB, Pasloske BL. Ribonuclease-resistant RNA controls (armored RNA) for reverse transcription-PCR, branched DNA, and genotyping assays for hepatitis C virus. Clin Chem 1999;45:2079–85.

8. Pasloske BL, Dubois DB, Brown DM, Winkler MM, inventors. Methods of quantifying viral load in an animal with a ribonuclease resistant viral RNA preparation. US Patent No. 6,399,307, issued June 4, 2002.

9. AsuraGen Diagnostics. Armored RNA products. http://www.asuragendx.com/products/armored_rna_other.html (accessed March 2006).

10. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 1989;77:61–8.

11. Li Q, Luan G, Guo Q, Liang J. A new class of homogeneous nucleic acid probes based on specific displacement hybridization. Nucleic Acids Res 2002;30:e5.

Qiuying Huang
Yangjian Cheng
Qiwei Guo
Qingge Li
Agreement between K-ras Sequence Variations Detected in Plasma and Tissue DNA in Pancreatic and Colorectal Cancer

To the Editor:
Several studies have identified DNA alterations in circulating plasma DNA of cancer patients that match genetic changes in primary tumors, but the low sensitivity obtained has limited the clinical application of plasma analysis (1, 2). A recent report in Clinical Chemistry (3) demonstrated that the method chosen to isolate plasma DNA, a modified guanidine/Promega resin (G/R) method, could increase detection of K-ras sequence variations in patients with colorectal disease. Using the same approach, another group (4) found no relationship between these isolation methods, nor between K-ras sequence variations found in DNA from plasma and tumor tissue in patients with non-small cell lung cancer. In a previous study (5), we found that plasma K-ras analysis was a highly specific, low-sensitivity approach with prognostic significance in pancreatic carcinoma.

To evaluate the agreement rate between K-ras sequence variations in plasma DNA and corresponding tissue, we used the Qiagen method to isolate DNA from 112 plasma samples from patients with pancreatic disease and from 87 plasma samples from patients with colorectal disease. We also isolated DNA from corresponding pancreatic cytology samples and colorectal tissues. The restriction fragment length polymorphism–PCR method used to detect K-ras sequence variations has been described previously (6). The concordant results between plasma and tissue are shown in Table 1.

In the patients with pancreatic adenocarcinoma, sensitivity for detecting K-ras sequence variations was 41% (34 of 82) in resected tissue samples. In the colorectal adenocarcinoma group, sensitivity for detecting K-ras sequence variations was 43% (19 of 44) in plasma samples and 87% (39 of 45) in fine-needle aspirate or pancreatic juice samples. No sequence variations were detected in plasma DNA from patients with chronic pancreatitis, acute pancreatitis, or other pancreatic neoplasms, giving a specificity of 100%. The agreement rate in pancreatic samples was 78% (19 positive and 67 negative; total, 86 of 110). Single-strand conformation polymorphism (SSCP) analysis allowed characterization of 11 of 19 positive plasma samples, and the spectrum was 8 GAT and 3 GTT. Concordant SSCP results were obtained in plasma and cytology samples. In the colorectal adenocarcinoma group, sensitivity for detecting K-ras sequence variations was 8.5% (7 of 82) in plasma samples and 41% (34 of 82) in resected tissue samples. In colorectal adenomas and diverticulosis, no variant sequences were detected in plasma or tissue. The agreement rate in colorectal plasma and tissue samples was 69% (7 positive and 53 negative; total, 60 of 87). Characterization was possible in 5 of 7 positive plasma samples (3 GAT, 1 GTT, and 1 CGT) and was concordant with results in tissue.

In addition, we performed our routine Qiagen assay method in parallel with the G/R method in a subset of 12 plasma samples (6 pancreatic and 6 colorectal adenocarcinomas) from the evaluated group (3 with the K-ras variant in each group). With the G/R

Table 1. Agreement rate between plasma and pancreatic or colorectal tissue.

| Diagnosis                        | n   | Plasma | Pancreatic (FNA* or PJ) or colorectal tissue |
|----------------------------------|-----|--------|---------------------------------------------|
| Pancreatic adenocarcinomas       | 45  | 19 (+) | 19 (+)                                      |
|                                  |     | 25 (-) | 5 (-)                                       |
|                                  |     | 1 (NA)c | 1 (-)                                      |
| Other pancreatic neoplasmsd     | 8   | 8 (-)  | 8 (-)                                       |
| Chronic pancreatitis             | 53  | 52 (-) | 48 (-)                                      |
|                                  |     | 1 (NA)c | 1 (-)                                      |
| Acute pancreatitis               | 6   | 6 (-)  | 6 (-)                                       |
| Colorectal adenocarcinomas       | 82  | 7 (+)  | 7 (+)                                       |
|                                  |     | 75 (-) | 48 (-)                                      |
|                                  |     |         | 27 (+)                                      |
| Colorectal adenomas              | 3   | 3 (-)  | 3 (-)                                       |
| Diverticulosis                   | 2   | 2 (-)  | 2 (-)                                       |

* (+): DNA sample contains detectable codon 12 K-ras mutation; (-), DNA sample does not contain detectable codon 12 K-ras mutation.
* FNA, fine needle aspirate; PJ, pancreatic juice.
* NA, nonamplified samples (in 2 plasma pancreatic samples amplification was not possible).
* Including 3 cholangiocarcinomas, 3 pancreatic metastases, and 2 neuroendocrine tumors.